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Introduction: Medical models assist clinicians in making diagnostic and prognostic deci-
sions in complex situations. In advanced ovarian cancer, medical models could help prevent
unnecessary exploratory surgery. We designed two models to predict suboptimal or complete
and optimal cytoreductive surgery in patients with advanced ovarian cancer.
Methods: We collected clinical, pathological, surgical, and residual tumor data from 110
patients with advanced ovarian cancer. Computed tomographic and laparoscopic data from
these patients were used to determine peritoneal cancer index (PCI) and lesion size score.
These data were then used to construct two-by-two contingency tables and our two predictive
models. Each model included three risk score levels; the R4 model also included operative
PCI, while the R3 model did not. Finally, we used the original patient data to validate the
models (narrow validation).
Results: Our models predicted suboptimal or complete and optimal cytoreductive surgery
with a sensitivity of 83% (R4 model) and 69% (R3 model). Our results also showed that
PCI>20 was a major risk factor for unresectability.
Conclusion: Our medical models successfully predicted suboptimal or complete and opti-
mal cytoreductive surgery in 110 patients with advanced ovarian cancer. Our models are easy
to construct, based on readily available laboratory test data, simple to use clinically, and
could reduce unnecessary exploratory surgery in this patient group.
Keywords: advanced ovarian cancer, medical model, peritoneal cancer index, cytoreductive
surgery
Introduction
A clinical model is a tool that quantifies the individual contribution of several
factors (clinical, analytical, radiological, etc.) when evaluating the diagnosis or
prognosis of a specific patient. Its purpose is to solve complex or uncertain
decisions in different scenarios, to give precise individual prognoses, and to save
costs without increasing risks for the patient. Its elaboration is mathematical, based
on the statistical association between certain factors and a result. The model
calculates the probabilities (predictive values) of obtaining a concrete result or
a certain degree of efficacy for a medical intervention.1,2
All models are constructed retrospectively on a wide range of already available
clinical information. Later, these models must be validated in different environ-
ments to verify their accuracy and generalize their usefulness. This is done by
analyzing the calibration between the expected results based on the model and the
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observed results, and their discrimination among opposite-
sign results. This proof of reproducibility and the confir-
mation of the likelihood of changing clinical decisions that
imply improved clinical results constitute the model’s
maximum degree of evidence.3
A determining factor for survival in advanced ovarian
cancer (AOC) is removal of the entire tumor burden to
achieve either complete removal of the tumor upon visual
inspection (complete cytoreductive surgery, CCS) or
a residual tumor of <1 cm (optimal cytoreductive surgery,
OCS). Only these two surgical outcomes improve
survival.4 But in the most advanced cases of disease, the
likelihood of obtaining CCS or OCS versus suboptimal
cytoreductive surgery (SCS) remains uncertain before or
even during the surgery. Specific imaging tests and laparo-
scopic exploration are fundamental when evaluating pos-
sibilities for OCS. When the probability of CCS is not
high, it is necessary to rely on neoadjuvant treatments that
decrease the tumor burden to allow for surgery.4
Accordingly, a SCS could be considered a surgical
failure in the attempt to improve survival and, therefore,
unnecessary high risk surgery. The objective of this study
was to build a model that combines and enhances the
information from imaging tests and laparoscopy to deter-
mine the probability of SCS versus CCS or OCS for each
patient. This may lead to a more appropriate choice of
therapeutic strategy. We also validated the model by ana-
lyzing the same data used for its construction (narrow
validation), as a first step before prospectively addressing
its reproducibility (broad validation) in subsequent studies
with new samples of patients.
Methods
Patients
110 consecutive patients diagnosed by CT-scan with AOC
were treated at the Multidisciplinary Unit of Abdominal
Pelvic Oncology Surgery (MUAPOS) of the University
General Hospital of Castellon, Spain from January 2013
to December 2016. We excluded patients meeting the
radiologic-laparoscopic criteria for unresectability
(RLCU)5 defined in preoperative studies (Table 1).
Patients older than 80 years and ECOG greater than 1
were also excluded. The same surgical team performed
preoperative laparoscopy and debulking surgery. In all
patients a A CT-scan was performed. The same radiolo-
gist evaluated the radiological PCI. Kappa concordance
index between radiological and laparoscopic PCI was
51%. Data describing patients’ clinical and pathological
characteristics, surgical procedures, and residual disease
at surgery were collected prospectively and analyzed
retrospectively.
Written informed consent was obtained from all
patients, and the Ethics Committee of the University
General Hospital of Castellon approved the study which
were guided by international and national ethical require-
ments concerning biomedical research. In addition to this,
the study was conducted in compliance with the
Declaration of Helsinki.
Predictive factors
Peritoneal cancer index (PCI) is used to quantitatively
assess cancer distribution in the peritoneum based on
calculating the sizes of lesions in 13 abdominopelvic
regions, as described before.6 The sizes of the lesions are
then converted to scores of 0–3: a lesion size score (LSS)
of 0 defines no visible tumor burden in the peritoneum,
while an LLS of 1, 2, or 3 describes lesions with
a maximum diameter of 0.5, 5.0, and >5 cm or lesion
confluence, respectively. PCI is calculated by adding the
LSS for all regions, giving a maximum PCI of 39 (13×3).7
PCI was determined in all patients in this study by
preoperative thoraco-abdominal computed tomography
(CT) (80 patients) and/or laparoscopy (49 patients). To
quantify the radiological PCI, we chose the largest tumor
implant in the assessed region and assigned a score of 0–3.
The sum of the scores for each region was then used to
calculate the radiological PCI. PCI was calculated before
and during surgery, and was categorized into three ordinal
levels: 1–10, 11–20, and >20. All specimens were col-
lected and labeled relative to PCI areas. Intestinal obstruc-
tion was defined clinically when the following signs were
present: abdominal distention, with nausea or vomiting
and absence of evacuation; and radiologically, with disten-
tion of the small or large bowel.
Table 1 Radiologic-laparoscopic criteria for unresectability (RLCU)
CT-scan Lung metastasis
Hepatic metastasis in 3 o more hepatic seg-
ments




Diffuse serous small bowel disease
Abbreviations: CT, computed tomography; NACT, neoadjuvant chemotherapy.
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CCS was defined as no residual macroscopic tumor,
OCS as a residual tumor <1 cm in diameter, and subopti-
mal cytoreductive surgery (SCS) as a residual tumor
>1 cm in diameter. Postoperative complications were
described according to the Clavien-Dindo classification,8
and grade IIIb–IV complications were considered major
complications. Patient follow-up began with the diagnosis.
First-line adjuvant chemotherapy involved all patients
receiving 6–8 cycles of intravenous carboplatin and placi-
taxel. After primary adjuvant chemotherapy, we evaluated
patients every 3–6 months. Relapse and response to first-
line chemotherapy were defined according to the guide-
lines for response evaluation criteria in solid tumors.9
Statistical analysis and model
development design
In this study, we use a method for developing a new model for
predicting SCS or CCS and OCS in AOC based on
Spiegelhalter and Knill-Jones’ method.10 The core of
Spiegelhalter and Knill-Jones’ method expresses the “weight
of evidence” because it combines the available patient infor-
mation with previous experience, while time prediction scores
are presented in a form (standardized weights) that is less
mathematical and more clinically relevant than conventional
logistic regression analysis.11 Two-by-two contingency tables
were constructed with the possible predictive factors derived
from staging tests and the result variable (type of cytoreduc-
tion) in binary form: in rows, PCI>20 vs PCI≤20 from radi-
ological-laparoscopic preoperative reports and surgical
findings, or presence vs absence of partial bowel obstruction,
ascites, and pleural effusion; in columns, suboptimal vs com-
plete and optimal debulking. Factors with p<0.10 based on the
Chi-square or Fisher’s exact test were selected to construct the
model. Subsequently, from the same contingency tables, we
calculated positive- and negative-probabilistic weights10,11
and their difference, setting the value (points) to 0 in the
absence of a factor or with PCI ≤20 (Table 2).
Based on the points for each factor, two suboptimal
cytoreductive risk models were constructed, depending on
inclusion or exclusion of the operative PCI. Low risk,
intermediate risk, or high risk was assigned for each
patient depending on the total points (Table 3).
Model performance
Validation (accuracy) of the model is analyzed through its
power of calibration and discrimination. Calibration refers
to the degree of coincidence between the expected
suboptimal cytoreduction by the model and the really
observed. Discrimination refers to the probability that the













CT PCI* 1 0 0.09 1
Laparoscopic PCI* 1 0 0.06 1
Operative PCI* 1 −1 0.0007 2
CT or clinical partial
bowel obstruction**
2 0 0.03 2
Notes: *Cut-off: PCI>20 vs PCI≤20. ** Presence vs Absence. ***Points: Difference
between positive-probabilistic weight (a) and negative-probabilistic weight (b). This
difference is the difference in natural logarithms for the positive- and negative-
likelihood ratios for suboptimal cytoreduction: [log (sensitivity/1−specificity)] −
[log (1−sensitivity/specificity)], setting the value to 0 in the absence of the risk factor.















CT or clinical absence of partial bowel obstruction
CT or clinical presence of partial bowel obstruction
0
2
Abbreviations: CT, computed tomography; PCI, peritoneal cancer index.
Table 3: Suboptimal cytoreductive risk models




Note: *(With operative peritoneal cancer index)




Note: *(Without operative peritoneal cancer index)
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model correctly distinguishes two opposite-sign results,
and is represented by the AUC.
The calibration and discrimination power of the model
was validated using the same data from the series (narrow
validation). Calibration was analyzed graphically, compar-
ing the observed SCS percentages and the levels of risk
predicted by the model. Discrimination was analyzed
using receiver operating characteristic curves from the
points assigned by the model and the observed presence
of SCS. Univariate logistic regression was used to calcu-
late how much the risk of suboptimal debulking increases
when adding a supplementary point in the total score,
where the odds ratio represents the multiplicative constant.
Statistical analysis was performed using MedCalc 15
for Windows (MedCalc Software, Ostend, Belgium).
Results
A total of 110 patients with suspected AOC were treated at
the MUAPOS at the University General Hospital of
Castellon, Spain from January 2013 to December 2016.
Among these, 80 patients where eligible for primary
debulking surgery and were included in this study. None
of the patients included in this study met our RLCU
criteria. We excluded 30 (27%) patients who met our
RLCU criteria; these patients received neoadjuvant che-
motherapy followed by interval debulking surgery
or second-line chemotherapy.
Patients’ clinicopathological and surgical characteris-
tics of are summarized in Table 4. Most patients presented
with serous (55%) and Federation of Gynecology and
Obstetrics stage IIIC (71%) epithelial ovarian cancer.
The aim of surgery was to achieve maximum tumor
debulking. At laparotomy, CCS and OCS were achieved in
64 (80%) and 5 (6%) patients, respectively, while SCS was
achieved in the remaining 11 (14%) patients. The surgical
procedures performed included abdominal and pelvic peri-
tonectomy in 54 (67%) patients, rectosigmoidectomy in 35
(43%), and large bowel resection in 40 (50%). Upper
abdominal surgery (UAS) was required in 57 (71%)
patients, including diaphragmatic peritonectomy in 40
(50%), distal pancreatectomy in 8 (10%), splenectomy in
23 (29%), and liver resection in 9 (11%).
Pelvic and aortic lymphadenectomy were performed in
59 patients (74%), with positive lymph nodes in the pelvic,
paraaortic, or both systems in 36 (61%) patients. Clavien-
Dindo Grade IIIb–IV complications were found in 25 (31%)
patients, with a higher incidence in patients with a PCI>10
(p<0.001). The main postoperative complications were of
intestinal origin (12%), including intestinal and pancreatic
leakage and colorectal anastomotic fistula. The 90-day post-
operative mortality was 3.7% (3 patients).
Calibration of the two models was made using the same
series data (narrow validation), which revealed different
rates of SCS at different risk levels (Figures 1 and 2).
Both models showed good SCS prediction at level 3 risk,
80% and 100% with model R4 and R3, respectively.
Discrimination of the two models showed good perfor-
mance (R4 area under the curve (AUC) =83% and R3
AUC=69%) when detecting SCS (Figures 3 and 4).
The predictive values derived from each model are
shown in Table 5. The risk of SCS is determined by the
positive predictive value. Given that the predictive values
for the same sensitivity and specificity depend on the
prevalence of SCS that can be achieved, Table 5 includes
different levels of prevalence with the corresponding pre-
dictive values derived from the sensitivity and specificity
of the model. The multiplicative probability constant for
the risk of SCS calculated by logistic regression is shown
in Table 6.
The multiplicative constant for the probability of SCS
produced by an added point in the total score is shown in
Table 6. For R3 and R4 models, each increment of 1 unit
in the total score multiplies the predicted risk of SCS by 8
and 10, respectively.
Discussion
Surgery remains the cornerstone of treatment for AOC, but
it is not applicable to all patients. Neoadjuvant chemother-
apy remains the best option for patients who are not
surgical candidates12 .The residual tumor after surgery
remains the most important prognostic factor in AOC,
and the decision between primary debulking surgery and
interval debulking surgery after neoadjuvant chemotherapy
remains the key point in surgical treatment in AOC.13,14 In
the MUAPOS guide to managing AOC, the preoperative
RLCU criteria define which patients receive neoadjuvant
chemotherapy.5 Therefore, in patients who are candidates
for primary surgery, preoperatively determining which
surgery will be optimal or suboptimal could be invaluable.
To select patients suitable for complete surgery and to
compare patient outcomes, surgeons need scoring systems
with an accurate description of the disease. The FIGO
staging system is inadequate for detailed assessment of
the extent of the peritoneal spread of carcinomatosis.
Therefore, detailed clinical scoring systems are needed
pre- and intraoperatively, and they are also necessary to
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standardize the procedure and compare the results among
different surgeons.
Considering a patient’s signs, symptoms, and test results,
comparing them with past experience, and arriving at
a reasoned decision defines clinical medicine. Scoring systems
are usually used in medicine to assist physicians with complex
diagnostic or therapeutic decisions. Individually, CT-PCI>20
offers an excellent false positive rate for SCS (Specificity 94%)
but its Sensitivity for SCS is low (27%), and its discrimination
power is intermediate (AUC 69%). Logically, when adding
other predictive factors of significant weight in the model, the
final result improves. In an isolated way, CT is more useful to
identify non-resectability than to predict SCS.6
Our dynamic model predicts either SCS or CCS and OCS
depending on the prevalence of the SCS of the surgical team,
and it changes with time depending on incorporating new
therapeutic approaches and technical innovations. Combining
sensitivity and specificity of the model with the actual preva-
lence of cytoreduction in a certain scenario (Bayes’ theorem),
we obtained the predictive values. Positive predictive value for
SCS is a simple probability but it is the one that must aid to
determine the decision to be taken according to its magnitude.
When handling binary variables, the sensitivity for SCS corre-
sponds to the specificity for CCS+OCS, and vice versa.
Therefore, the negative predictive value of SCS corresponds
to the positive predictive value for CCS+OCS. In summary,
Table 4 Patients’ clinicopathologic and surgical characteristics
CCS and OCS (n=69) SCS (n=11) TOTAL (n=80)
Age (years±SD) 60±11 58±10 60±11
FIGO stage, n (%)
IIIC 53 (27%) 4 (36%) 57 (71%)
IV 16 (23%) 7 (64%) 23 (29%)
CT-PCI 10±6 15±7 11±7
Categorized CT-PCI, n (%)
1–10 44 (64%) 5 (46%) 49 (61%)
10–20 21 (30%) 3 (27%) 24 (30%)
> 20 4 (6%) 3 (27%) 7 (9%)
CT Ascites, n (%) 18 (26%) 4 (36%) 22 (28%)
Clinical-CT Partial Bowel Obstruction, n (%) 3 (4%) 3 (27%) 6 (8%)
CT Pleural Effusion, n (%) 10 (14%) 2 (18%) 12 (15%)
Laparoscopic PCI, n (%)
1–10 20 (49%) 0 20 (41%)
10–20 18 (44%) 5 (62%) 23 (47%)
>20 3 (7%) 3 (38%) 6 (12%)
Operative PCI, n±SD 12±8 23±10 14±9
Categorized Operative PCI, n (%)
1–10 32 (46%) 2 (18%) 34 (43%)
10–20 24 (35%) 1 (9%) 25 (31%)
>20 13 (19%) 8 (73%) 21 (26%)
Visceral Resections per patient, n±SD 3±3 4±4 3±3
Analyzed Lymph Nodes, n±SD 26±14 29±18 26±15
Lymph Node Ratio, n±SD 0.25±0.29 0.33±0.38 0.26±0.30
All Postoperative Complications, n (%) 38 (55%) 7 (64%) 45 (56%)
Postoperative 90-day Mortality, n (%) 2 (3%) 1 (9%) 3 (3.7%)
Abbreviations: CCS, complete cytoreductive surgery; OCS, optimal cytoreductive surgery; SCS, suboptimal cytoreductive surgery; SD, standard deviation; FIGO,
Federation of Gynecology and Obstetrics; CT, computed tomography; PCI, peritoneal cancer index.
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positive predictive values for SCS and CCS+OCS represent
the predicted final diagnosis by a model in different scenarios
of achieved cytoreduction. These values based on our data are
shown in Table 5. This means that in scenarios with low SCS
prevalence, the model is more reliable for predicting CCS and
OCS than SCS, whereas with higher SCS rates, the model will
better predict SCS. Therefore, with low SCS prevalence, a low
score ensures CCS and OCS, while a high score does not
ensure SCS. Conversely, with high SCS prevalence, a high
score predicts a high risk of SCS while a low score leaves
uncertainty regarding the possibility of achieving CCS and
OCS. The prevalence of better or worse cytoreduction depends
on how advanced the disease is and physicians’ surgical skill.
Therefore, the degree of cytoreduction may differ from one
working group to another, and we cannot expect that the same
model will work equally in all environments. This is also why
models must be validated in each environment to prove their
usefulness beforehand.Only if amodelworkswell in a specific
environment, will it reach itsmaximumdegree of evidence and
have universal impact.3 The multiplicative constant for the
probability of SCS produced by an added point in the total
score is shown in Table 6 and proves that the group of selected
predictive factors is essential for predicting the final analyzed
outcome.
Evaluating PCI in preoperative CT scans has been investi-
gated in several studies showing that PCI was useful when
planning surgery.15 However, these results are more variable
when predicting outcome. Each of the published series
reported different positive predictive values for SCSdepending
on the rate of OCS of the surgical team.16–18 In our data,
CTPCI was useful when determining PCI>20 and/or intestinal
obstruction in preoperative studies, as both were important
prognostic factors for a CCS and OCS rate of 86%.
Several scores have been described to determine the extent
of disease and to predict resectability including Alleti, PCI,
Eisenkop, and Fagotti models.7,19–21 The most widely-used
Observed Cytoreduction
Risk Groups R4 Complete+Optimal Suboptimal
1 52 (96%) 2 (4%)
2 16 (76%) 5 (24%)


















Figure 1 Calibration R4 model.
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scores are the Fagottimodel and PCI scores. The Fagottimodel
describes a laparoscopic model based on a score of 0–12 for
progressive disease. The authors reported an overall OCS rate
of 67%with an accuracy of 69%when the score was >10 with
a 34% unnecessarily-explored rate. External validation of this
scorewas performed byBrun et alwho reported anOCS rate of
69% with a decreased accuracy of 60% in model results.
Recently, Petrillo et al updated the Fagotti score with an
increase in their OCS rate to 80% by introducing UAS. Once
again, the key point is the relationship between surgeon-related
factors and the surgical outcome.22,23
Our data demonstrated that laparoscopic PCI>20 is amajor
risk factor for unresectability. Nevertheless, as do other
authors, we believe that laparoscopy alone lacks in describing
several anatomical regions of the abdomen. Lesions in the
retrohepatic area, suprahepatic veins, retroperitoneal space
and/or infiltration of the liver pedicle may be underestimated
while the presence of these findings is a major determining
factor for suboptimal cytoreduction. In the specific areas, CT
could play a crucial role to avoid unnecessary laparotomy and
too for neoadjuvant chemotherapy.6,24
Chéreau et al25 demonstrated a strong correlation between
Fagotti score and PCI at laparotomy when describing tumor
distribution in the abdominal cavity and compared the different
models when predicting resectability in AOC. The authors
reported an AUC rate of 56% and 51% for PCI and Fagotti
score, respectively. Combining CT and laparoscopy, our R4
and R3 models produced AUC rates of 83% and 69%, respec-
tively, when discriminating SCS from CCS and OCS.
The strengths of our study lie in the investigation, design
strategy, and performance of our two dynamic clinical-
radiological-laparoscopic models to predict suboptimal (or
complete and optimal) debulking surgery in a homogeneous
cohort of patients with primary epithelial ovarian cancer trea-
ted in a university hospital with a surgical team experienced in
AOC. We propose an easily-constructed model based on the
Observed Cytoreduction
Risk Groups R3 Complete + Optimal Suboptimal
1 63 (91%) 6 (9%)
2 6 (60%) 4 (40%)


















Figure 2 Calibration R3 model.
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diagnostic tests usually used in these patients. The dynamic
nature of themodelsmeans that they can be applied in different
institutions with different OCS or SCS rates, and they can be
changed with changes in the SCS prevalence of the surgical
team. The proper integration of the R3 and R4 models with
recently developed molecular26 and clinical-radiological
models,27 including age, performance status, and comorbid-
ities may help improve the decision-making process in the
future. Suidan et al27 use several radiological criteria, in addi-
tion to other clinical criteria, to predict SCS in a more compli-
cated model. This differs greatly from the calculation of
a radiological PCI, although the substrate can be considered
similar. However, we believe that some of these criteria are
more relatedwith unresectability thanwith suboptimal surgery.
The limitations of our study are the retrospective com-
ponent, small number of patients, and the absence of a broad
validation of the models. However, because of the important
impact of SCS in prognosis in AOC treatment, our models
could be of clinical interest to reduce the number of unne-
cessary laparotomic explorations. Broad validation of the
models in a large number of patients remains necessary,
which may be addressed in the near future.
Conclusion
Our findings emphasize that the proper application of our
R3-R4 models in primary debulking surgery requires max-
imal surgical effort including UAS techniques and well-
prepared multidisciplinary surgical teams. These two mod-
els can predict CCS+OCS and SCS, depending on the SCS
prevalence of the surgical team.
Abbreviation list
AOC, advanced ovarian cancer; AUC, area under
curve; CCS, complete cytoreductive surgery; LSS,
lesion size score; MUAPOS, Multidisciplinary Unit of
Abdominal Pelvic Oncology Surgery; OCS, optimal
cytoreductive surgery; PCI, peritoneal cancer index;
SCS, suboptimal cytoreductive surgery; UAS, upper
abdominal surgery.
ROC: Area Under the Curve 0.83 
Standard Error 0.076 
95% Confidence Interval 0.72 to 0.90 
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Figure 3 Discrimination R4 model.
ROC: Area Under the Curve 0.69 
Standard Error 0.099 
95% Confidence Interval 0.57 –0.79 
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Figure 4 Discrimination R3 model.
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